TheraRadar

Arcus

Pre-Approval PRO BETA
29
Total Trials
3
Phase 3
5
Phase 2
9
Recruiting
164
Score

Pipeline by Phase

Phase 3
3
Phase 2
5
Phase 1
23

Therapeutic Focus

Healthy Participants Ovarian Cancer Non Small Cell Lung Cancer Advanced Cancer Bladder Cancer

Clinical Trials (29)

NCT07011719 Phase 3 RECRUITING

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

Started: 9/8/2025

NCT05568095 Phase 3 ACTIVE NOT RECRUITING

A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body

Started: 11/21/2022

NCT06608927 Phase 3 ACTIVE NOT RECRUITING

Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Started: 12/13/2024

NCT04736173 Phase 2 ACTIVE NOT RECRUITING

Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer

Started: 2/8/2021

NCT05329766 Phase 2 ACTIVE NOT RECRUITING

A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies

Started: 6/10/2022

NCT04262856 Phase 2 COMPLETED

Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer

Started: 5/28/2020

NCT05536141 Phase 1 RECRUITING

A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

Started: 10/26/2022

NCT06120075 Phase 1 ACTIVE NOT RECRUITING

A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies

Started: 1/19/2024

NCT04104672 Phase 1 ACTIVE NOT RECRUITING

A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies

Started: 11/6/2019

NCT05891171 Phase 1 ACTIVE NOT RECRUITING

Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers

Started: 10/13/2023

NCT07364214 Phase 1 COMPLETED

Metabolism, Excretion, and Mass Balance Study of Quemliclustat in Healthy Adult Participants (ARC-24)

Started: 2/3/2026

NCT06919991 Phase 1 COMPLETED

Drug-Drug Interaction Study of Casdatifan in Healthy Adult Participants (ARC-29)

Started: 5/2/2025

NCT04660812 Phase 1 COMPLETED

An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.

Started: 5/10/2021

NCT04772989 Phase 1 COMPLETED

A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies

Started: 3/19/2021

NCT04381832 Phase 1 COMPLETED

Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

Started: 7/7/2020

NCT03628677 Phase 1 COMPLETED

A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies

Started: 9/12/2018

NCT03846310 Phase 1 COMPLETED

A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer

Started: 4/1/2019

NCT05999513 Phase 1 COMPLETED

A Relative Bioavailability Study and Food Effect Study of AB521 in Healthy Adult Volunteers

Started: 8/21/2023

NCT05117554 Phase 1 COMPLETED

Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile With Oral AB521 in Healthy Volunteers

Started: 11/9/2021

NCT04087018 Phase 1 COMPLETED

Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors

Started: 9/24/2019

NCT06004921 Phase 1 COMPLETED

A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AB801 in Healthy Volunteers

Started: 10/16/2023

NCT04575311 Phase 1 COMPLETED

A Study to Investigate the Pharmacokinetic Profile of Oral AB680 in Healthy Volunteers

Started: 10/20/2020

NCT03719326 Phase 1 COMPLETED

A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies

Started: 10/15/2018

NCT05277012 Phase 1 COMPLETED

A Study to Evaluate Pharmacokinetics (PK) of Etrumadenant Tablet and Capsule Formulations in Healthy Adult Participants

Started: 2/10/2022

NCT03720678 Phase 1 COMPLETED

A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal Malignancies

Started: 11/18/2018

NCT05411146 Phase 1 COMPLETED

A Study Investigating the Safety, Absorption, and Elimination of Radioactively Labeled Etrumadenant, a New Compound in the Treatment of Cancer

Started: 5/25/2022

NCT03677973 Phase 1 COMPLETED

A Study to Investigate the Safety of AB680 in Healthy Volunteers

Started: 10/16/2018

NCT03629756 Phase 1 COMPLETED

A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies

Started: 7/24/2018

NCT05154136 Phase 1 COMPLETED

A Drug-Drug Interaction Study to Evaluate the Effect of Itraconazole on the Pharmacokinetic Profile of Etrumadenant in Healthy Adult Participants

Started: 10/20/2021

Drug Candidates

Domvanalimab Zimberelimab Capecitabine Fluorouracil Leucovorin Oxaliplatin Nivolumab Casdatifan Cabozantinib Placebo
Activity Status: Active
Last Trial Started: 2/3/2026
Last Trial Ended: 4/6/2026
Trials (12 months): 2
Completed Trials: 20
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.